Steiner Johann, Bernstein Hans-Gert, Bielau Hendrik, Berndt Annika, Brisch Ralf, Mawrin Christian, Keilhoff Gerburg, Bogerts Bernhard
Department of Psychiatry, University of Magdeburg, Leipziger Str, 44, D-39120 Magdeburg, Germany.
BMC Neurosci. 2007 Jan 2;8:2. doi: 10.1186/1471-2202-8-2.
S100B is considered an astrocytic in-situ marker and protein levels in cerebrospinal fluid (CSF) or serum are often used as biomarker for astrocytic damage or dysfunction. However, studies on S100B in the human brain are rare. Thus, the distribution of S100B was studied by immunohistochemistry in adult human brains to evaluate its cell-type specificity.
Contrary to glial fibrillary acidic protein (GFAP), which selectively labels astrocytes and shows only faint ependymal immunopositivity, a less uniform staining pattern was seen in the case of S100B. Cells with astrocytic morphology were primarily stained by S100B in the human cortex, while only 20% (14-30%) or 14% (7-35%) of all immunopositive cells showed oligodendrocytic morphology in the dorsolateral prefrontal and temporal cortices, respectively. In the white matter, however, most immunostained cells resembled oligodendrocytes [frontal: 75% (57-85%); temporal: 73% (59-87%); parietal: 79% (62-89%); corpus callosum: 93% (86-97%)]. S100B was also found in ependymal cells, the choroid plexus epithelium, vascular endothelial cells, lymphocytes, and several neurones. Anti-myelin basic protein (MBP) immunolabelling showed an association of S100B with myelinated fibres, whereas GFAP double staining revealed a distinct subpopulation of cells with astrocytic morphology, which solely expressed S100B but not GFAP. Some of these cells showed co-localization of S100B and A2B5 and may be characterized as O2A glial progenitor cells. However, S100B was not detected in microglial cells, as revealed by double-immunolabelling with HLA-DR.
S100B is localized in many neural cell-types and is less astrocyte-specific than GFAP. These are important results in order to avoid misinterpretation in the identification of normal and pathological cell types in situ and in clinical studies since S100B is continuously used as an astrocytic marker in animal models and various human diseases.
S100B被认为是一种星形胶质细胞原位标志物,脑脊液(CSF)或血清中的蛋白水平常被用作星形胶质细胞损伤或功能障碍的生物标志物。然而,关于人脑中S100B的研究很少。因此,本研究采用免疫组织化学方法研究S100B在成人大脑中的分布,以评估其细胞类型特异性。
与选择性标记星形胶质细胞且仅显示微弱室管膜免疫阳性的胶质纤维酸性蛋白(GFAP)相反,S100B的染色模式不太均匀。在人类皮质中,具有星形胶质细胞形态的细胞主要被S100B染色,而在背外侧前额叶皮质和颞叶皮质中,所有免疫阳性细胞中分别只有20%(14%-30%)或14%(7%-35%)显示少突胶质细胞形态。然而,在白质中,大多数免疫染色细胞类似于少突胶质细胞[额叶:75%(57%-85%);颞叶:73%(59%-87%);顶叶:79%(62%-89%);胼胝体:93%(86%-97%)]。S100B也存在于室管膜细胞、脉络丛上皮、血管内皮细胞、淋巴细胞和一些神经元中。抗髓鞘碱性蛋白(MBP)免疫标记显示S100B与有髓纤维有关,而GFAP双重染色显示有一群具有星形胶质细胞形态的细胞,它们仅表达S100B而不表达GFAP。其中一些细胞显示S100B和A2B5共定位,可能被表征为少突胶质前体细胞(O2A)。然而,通过与HLA-DR双重免疫标记发现,小胶质细胞中未检测到S100B。
S100B定位于多种神经细胞类型,且与GFAP相比,其星形胶质细胞特异性较低。由于S100B在动物模型和各种人类疾病中一直被用作星形胶质细胞标志物,这些重要结果有助于避免在原位和临床研究中对正常和病理细胞类型的识别产生误解。